Validation Of The Leicester Cough Questionnaire In Non-cystic Fibrosis Ronchiectasis

Objectives:To understand the quality of life of non-cystic fibrosis bronchiectasis patients,quantize symptoms severity,evaluation of treatment effect real-timely,and guide clinical therapy,we verify the LCQ for evaluating patient responsiveness and effectiveness of the treatment effect in the study.And discuss the possible correlation between LCQ score and the severity and prognosis of bronchiectasis to provide reliable basis to prevent disease progression.Methods:Selected 62 patients with non-cystic fibrosis bronchiectasis who were admitted into the respiratory department of First Affiliated Hospital of Anhui Medical University in July 2014-July 2015 due to the acute exacerbation of bronchiectasis.All the research objects accepted the detailed medical history collection and physical examination after admission,and the patients'gender,age,height,weight,education background,smoking history,disease history,and sputum volume within24 hours were recorded.All the research objects accepted the inflammatory index examination at the acute exacerbation phase of bronchiectasis after admission,and the White Blood Cell?WBC?,C-Reactive Protein?CRP?and Procalcitonin?PCT?were collected in the blood routine examination;completed LCQ and pulmonary function test,and collected the forced vital capacity,?FVC?,predicted percentage of forced vital capacity?FVC%?,forced expiratory volume in one second?FEV1?,predicted percentage of forced expiratory volume in one second?FEV1%?,the ratio between forced expiratory volume in one second and forced expiratory volume?FEV1/FVC?,and total lung capacity?TLC?,retested and collected the above indexes after the 14-day clinical regular treatment.Results:1.General informationIn this research,there were 33 male cases,accounting for 53.2%,and 29female cases,accounting for 46.7%.The youngest one was 33 years old,while the oldest one was 82 years old with the average of 63.6±12.3 years old.The patients older than 60 years old accounted for 85.5%of the total?53/62?,including 36 female patients and 27 male patients.All patients'disease history ranged from 5 months to 46 years with the average of18.2±11.1 years.There were 41 cases with smoking history,accounting for66%of the total.The number of acute exacerbation was 1.8±0.6 on average.2.The white blood cell count at the acute phase?10.95±2.98?*10^12/L,at the stable phase?6.53±2.10?*10^12/L;the serum log10hsCRP at the acute phase?1.88±0.12?,at the stable phase?1.24±0.10?;the serum PCT at the acute phase?2.53±0.53?ng/ml,at the stable phase?0.77±0.15?ng/ml.Compared to that at the acute exacerbation phase,the indexes at the stable phase were significantly lower?p<0.01?.3.LCQ score of 62 patients at the acute exacerbation phase?11.25±1.49?:the mental score?3.43±0.71?,physical score?3.95±0.88?,social score?3.87±0.87?.At the stable phase?15.17±1.81?points:the mental score?5.25±0.86?,physical score?4.77±0.74?,social score?5.15±1.01?.After the acute exacerbation treatment,the psychological health,physical health and social feelings of patients with bronchiectasis were improved significantly?P<0.05?.4.62 patients accepted the pulmonary function test,including 8 cases with normal respiratory function,10 cases with restrictive respiratory dysfunction,16 cases with mixed respiratory dysfunction,and 28 cases with obstructive respiratory dysfunction.The average value at the acute exacerbation phase:FEV1?1.46±0.37?L,FEV1%pred?47.22±6.63?%,FVC%pred?64.36±10.74?L,FEV1/FVC?51.58±5.87?%;at the stable phase:FEV1?2.02±0.87?L,FEV1%pred?68.61±8.91?%,FVC%pred?71.48±11.53?L,FEV1/FVC?70.51±6.33?%.FEV1,FEV1%pred and FEV1/FVC and FVC%were improved significantly at the stable phase,but TLC%was not improved obviously.5.SGRQ total scoreat acute exacerbation phase 26.23±15.85,shows a significant correlation with the LCQ total score at acute exacerbation phase?r=-0.703,P<0.01?.SGRQ total score at stable phase 36.22±19.07shows a significant correlation with the LCQ total score at stable phase?r=-0.687,P<0.01?.6.Through comparing the LCQ score difference before and after the treatment and the index difference before and after the treatment,it could be seen that the LCQ evaluation change of patients with bronchiectasis at the stable phase and acute phase was significantly negatively related to WBC,Log₁₀CRP level and PCT level,and the LCQ evaluation change was positively related to the pulmonary function FEV₁%pred?r=0.502,P<0.01?.7.LCQ score at acute exacerbation phase?r=0.580,P<0.580?and stable phase?r=0.567,P<0.01?both shows a good correlation.with FEV1%pred.Conclusion:In the study of 62 patients with non-cystic fibrosis bronchiectasis,the change of LCQ score before and after treatment showed a good correlation with the WBC count and serum level of PCT,log10CRP,FEV1%pred.Proved LCQ an effective,reliable and sensitive HRQoL questionnaire which can assess the therapeutic effect of non-cystic fibrosis bronchiectasis from different aspects.LCQ scores at acute exacerbation phase?r=0.580,P<0.580?and stable phase?r=0.567,P<0.01?both reflect a good correlation with SGRQ scores and have the advantages of simple and easy to understand,easy to repeat.We think the LCQ can replace SGRQ to evaluate the curative effect of bronchiectasis.LCQ shows a good relevance with FEV1%pred,which prove LCQ can assess the severity and prognosis of bronchiectasis effectivity.LCQ should be finished both in acute phase and stable phase.Repeat LCQ can longitudinal identify whether there is acute exacerbation,knowledge the severity of the acute phase,estimate the pulmonary function to know the progress and prognosis of the disease.LCQ can be used as an effective tool to assess the long-term treatment effect.